Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic β-adrenergic stimulation

Journal of Cardiovascular Pharmacology

Volumn 41, Issue SUPPL. 1, 2003, Pages

  Ido, Akira ^a   Hasebe, Naoyuki ^a   Takeuchi, Toshiharu ^a   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Methyl iodophenyl pentadecanoic acid; Angiotensin II type 1 receptor blocker; Angiotensin converting enzyme inhibitor; Cardiac hypertrophy; Isoproterenol; Meta iodobenzylguanidine

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA METHYL IODOPHENYL PENTADECANOIC ACID I 131; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOPRENALINE; OLMESARTAN; TEMOCAPRIL; TETROFOSMIN TC 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; BETA ADRENERGIC STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; FATTY ACID METABOLISM; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HUMAN; HUMAN CELL; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; RAT; STATISTICAL SIGNIFICANCE; SYMPATHETIC NERVE;

ADRENERGIC FIBERS; ANIMALS; CARDIOMEGALY; FATTY ACIDS; IMIDAZOLES; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; TETRAZOLES; THIAZEPINES;

EID: 0037215681     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Zierhut W, Zimmer HG. Significance of myocardial α- and β-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989;65:1417-25.
2. Taylor PB, Tang Q. Development of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol 1984;62:384-9.
3. Fei L, Slade AK, Prasad K, et al. Is there increased sympathetic activity in patients with hypertrophic cardiomyopathy? J Am Coll Cardiol 1995;26:472-80.
4. Kuwahara T, Hamada M, Hiwada K. Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J Nucl Med 1998;39:1486-91.
5. Kagaya Y, Kanno Y, Takeyama D, et al. Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats: A quantitative autoradiographic study. Circulation 1990;81:1353-61.
6. 123I-MIBG myocardial scintigraphy in patients with hypertrophic cardiomyopathy. Jpn J Nucl Med 1997;34:807-14.
7. Antonaccio MJ, Kerwin L. Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats. Eur J Pharmacol 1980;68:209-12.
8. Baker KM, Chernin MI, Wixson SK, et al. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990;259:H324-32.
9. Takatsu H, Uno Y, Fujiwara H. Modulation of left ventricular iodine-125-MIBG accumulation in cardiomyopathic Syrian hamsters using the renin-angiotensin system. J Nucl Med 1995;36:1055-61.
10. Dae M, O'Connell IW, Botvinick EH, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 1989;79:634-44.
11. Knapp FF, Ambrose KR, Goodman MM, et al. New radioiodinated methyl-branched fatty acids for cardiac studies. Eur J Nucl Med 1986;12:S39-44.
12. Fujibayashi Y, Yonekura Y, Takemura Y, et al. Myocardial accumulation of iodinated bete-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S) methyl pentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 1990;31:1818-22.
13. Kirschner AS, Ice RD, Beierwaltes WH. Reply. J Nucl Med 1975;16:248-9.
14. 123I-metaiodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 1990;119:1329-37.
15. Ganguly PK, Sherwood GR. Noradrenaline turnover and metabolism in myocardium following aortic constriction in rats. Cardiovasc Res 1991;25:579-85.
16. Robinovitch MA, Rose CP, Schwab AJ, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
17. Alaoui-Talibi ZE, Guendouz A, Moravec M, et al. Control of oxidative metabolism in volume-overloaded rat hearts: Effect of propionyl-L-carnitine. Am J Physiol 1997;272:H1615-24.
18. Vork MM, Trigault N, Snoeckx LHEH, et al. Heterogeneous distribution of fatty acid-binding protein in the hearts of Wistar Kyoto and spontaneously hypertensive rats. J Mol Cell Cardiol 1992;24:317-21.
19. Sack MN, Rader TA, Park S, et al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996;94:2837-42.
20. Rockman HA, Wachhorst SP, Mao L, et al. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994;266:H2468-75.
21. Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42.
22. Ohta T, Hasebe N, Tsuji S, et al. Effects of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor blocker on cardiac dysfunction induced by isoproterenol in dogs. J Cardiovasc Pharmacol 2001;38(suppl 1):S63-7.
23. Nagano M, Higaki J, Nakamura F, et al. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension 1992;19:708-12.
24. Ono T, Kohya T, Tsukamoto E, et al. Improvement in fatty acid utilization in relation to a change in left ventricular hypertrophy in spontaneously hypertensive rats. Jpn Circ J 2000;64:117-20.
25. Hollenberg NK. Implications of species difference for clinical investigation: Studies on the renin-angiotensin system. Hypertension 2000;35:150-4.